Association between serotonin transporter polymorphisms (5-HTTLPR) and the MADRS Dysphoria, Retardation, and Vegetative Subscale scores in the treatment of depression

Hitoshi Takahashi,1 Hisashi Higuchi,2 Kazuhiro Sato,3 Mitsuhiro Kamata,3 Keizo Yoshida,4 Katsuji Nishimura1 1Department of Neuropsychiatry, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, 2Suzuki Jikoh Hospital, Ome-shi, Tokyo, 3Akita Kaiseikai Hospital, Akita-shi, 4Heal...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Takahashi H, Higuchi H, Sato K, Kamata M, Yoshida K, Nishimura K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Serotonin transporter polymorphism dysphoria score antidepressants MADRS Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/6fea310e430f4976929ff0c2c58aea28
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6fea310e430f4976929ff0c2c58aea28
record_format	dspace
spelling	oai:doaj.org-article:6fea310e430f4976929ff0c2c58aea282021-12-02T01:05:45ZAssociation between serotonin transporter polymorphisms (5-HTTLPR) and the MADRS Dysphoria, Retardation, and Vegetative Subscale scores in the treatment of depression1178-2021https://doaj.org/article/6fea310e430f4976929ff0c2c58aea282017-06-01T00:00:00Zhttps://www.dovepress.com/association-between-serotonin-transporter-polymorphisms-5-httlpr-and-t-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Hitoshi Takahashi,1 Hisashi Higuchi,2 Kazuhiro Sato,3 Mitsuhiro Kamata,3 Keizo Yoshida,4 Katsuji Nishimura1 1Department of Neuropsychiatry, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, 2Suzuki Jikoh Hospital, Ome-shi, Tokyo, 3Akita Kaiseikai Hospital, Akita-shi, 4Health Care Promotion Division, DENSO Corporation, Kariya-shi, Aichi, Japan Objective: We investigated the association between serotonin- or 5-hydroxytryptamine (5-HT)-related gene polymorphisms and response to antidepressant treatment in a specific symptom cluster of major depression by using the three-factor model of the Montgomery–Åsberg Depression Rating Scale (MADRS), ie, dysphoria (items of sadness, pessimistic thoughts, and suicidal thoughts), retardation (items of lassitude, inability to feel, apparent sadness, and concentration difficulties), and vegetative symptoms (items of reduced sleep, reduced appetite, and inner tension). Methods: This study was an open-label and nonrandomized trial. A total of 160 patients with baseline MADRS scores of ≥21, who were treated with fluvoxamine or milnacipran for 6 weeks, were included in the statistical analysis. Polymorphisms within a 5-HT transporter (5-HTT) gene-linked polymorphic region (5-HTTLPR), a variable number of tandem repeats in the second intron of the 5-HTT gene (5-HTTVNTR), and 5HT2A receptor (1438G/A) were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Results: The 5-HTTLPR polymorphisms affected the MADRS score change in dysphoria, but not in retardation, vegetative, or total symptoms. Dysphoria scores significantly decreased in patients with the S/S genotype compared to those in patients with the short (S)/long (L) + L/L genotype. However, 5-HTTVNTR and 1438G/A polymorphisms were not significantly associated with the treatment response to any cluster of depressive symptoms. When a Bonferroni correction was made, however, our results did not reach the criteria for statistical significance. Conclusion: The use of a single total depression rating scale may not be sufficient to accurately estimate the clinical response to antidepressants. Analyzing a subset of symptoms in psychological scales could be important when performing pharmacogenetic studies. Keywords: serotonin transporter polymorphism, dysphoria score, antidepressants, MADRSTakahashi HHiguchi HSato KKamata MYoshida KNishimura KDove Medical PressarticleSerotonin transporter polymorphismdysphoria scoreantidepressantsMADRSNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 13, Pp 1463-1469 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Serotonin transporter polymorphism dysphoria score antidepressants MADRS Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Serotonin transporter polymorphism dysphoria score antidepressants MADRS Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Takahashi H Higuchi H Sato K Kamata M Yoshida K Nishimura K Association between serotonin transporter polymorphisms (5-HTTLPR) and the MADRS Dysphoria, Retardation, and Vegetative Subscale scores in the treatment of depression
description	Hitoshi Takahashi,1 Hisashi Higuchi,2 Kazuhiro Sato,3 Mitsuhiro Kamata,3 Keizo Yoshida,4 Katsuji Nishimura1 1Department of Neuropsychiatry, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, 2Suzuki Jikoh Hospital, Ome-shi, Tokyo, 3Akita Kaiseikai Hospital, Akita-shi, 4Health Care Promotion Division, DENSO Corporation, Kariya-shi, Aichi, Japan Objective: We investigated the association between serotonin- or 5-hydroxytryptamine (5-HT)-related gene polymorphisms and response to antidepressant treatment in a specific symptom cluster of major depression by using the three-factor model of the Montgomery–Åsberg Depression Rating Scale (MADRS), ie, dysphoria (items of sadness, pessimistic thoughts, and suicidal thoughts), retardation (items of lassitude, inability to feel, apparent sadness, and concentration difficulties), and vegetative symptoms (items of reduced sleep, reduced appetite, and inner tension). Methods: This study was an open-label and nonrandomized trial. A total of 160 patients with baseline MADRS scores of ≥21, who were treated with fluvoxamine or milnacipran for 6 weeks, were included in the statistical analysis. Polymorphisms within a 5-HT transporter (5-HTT) gene-linked polymorphic region (5-HTTLPR), a variable number of tandem repeats in the second intron of the 5-HTT gene (5-HTTVNTR), and 5HT2A receptor (1438G/A) were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Results: The 5-HTTLPR polymorphisms affected the MADRS score change in dysphoria, but not in retardation, vegetative, or total symptoms. Dysphoria scores significantly decreased in patients with the S/S genotype compared to those in patients with the short (S)/long (L) + L/L genotype. However, 5-HTTVNTR and 1438G/A polymorphisms were not significantly associated with the treatment response to any cluster of depressive symptoms. When a Bonferroni correction was made, however, our results did not reach the criteria for statistical significance. Conclusion: The use of a single total depression rating scale may not be sufficient to accurately estimate the clinical response to antidepressants. Analyzing a subset of symptoms in psychological scales could be important when performing pharmacogenetic studies. Keywords: serotonin transporter polymorphism, dysphoria score, antidepressants, MADRS
format	article
author	Takahashi H Higuchi H Sato K Kamata M Yoshida K Nishimura K
author_facet	Takahashi H Higuchi H Sato K Kamata M Yoshida K Nishimura K
author_sort	Takahashi H
title	Association between serotonin transporter polymorphisms (5-HTTLPR) and the MADRS Dysphoria, Retardation, and Vegetative Subscale scores in the treatment of depression
title_short	Association between serotonin transporter polymorphisms (5-HTTLPR) and the MADRS Dysphoria, Retardation, and Vegetative Subscale scores in the treatment of depression
title_full	Association between serotonin transporter polymorphisms (5-HTTLPR) and the MADRS Dysphoria, Retardation, and Vegetative Subscale scores in the treatment of depression
title_fullStr	Association between serotonin transporter polymorphisms (5-HTTLPR) and the MADRS Dysphoria, Retardation, and Vegetative Subscale scores in the treatment of depression
title_full_unstemmed	Association between serotonin transporter polymorphisms (5-HTTLPR) and the MADRS Dysphoria, Retardation, and Vegetative Subscale scores in the treatment of depression
title_sort	association between serotonin transporter polymorphisms (5-httlpr) and the madrs dysphoria, retardation, and vegetative subscale scores in the treatment of depression
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/6fea310e430f4976929ff0c2c58aea28
work_keys_str_mv	AT takahashih associationbetweenserotonintransporterpolymorphisms5httlprandthemadrsdysphoriaretardationandvegetativesubscalescoresinthetreatmentofdepression AT higuchih associationbetweenserotonintransporterpolymorphisms5httlprandthemadrsdysphoriaretardationandvegetativesubscalescoresinthetreatmentofdepression AT satok associationbetweenserotonintransporterpolymorphisms5httlprandthemadrsdysphoriaretardationandvegetativesubscalescoresinthetreatmentofdepression AT kamatam associationbetweenserotonintransporterpolymorphisms5httlprandthemadrsdysphoriaretardationandvegetativesubscalescoresinthetreatmentofdepression AT yoshidak associationbetweenserotonintransporterpolymorphisms5httlprandthemadrsdysphoriaretardationandvegetativesubscalescoresinthetreatmentofdepression AT nishimurak associationbetweenserotonintransporterpolymorphisms5httlprandthemadrsdysphoriaretardationandvegetativesubscalescoresinthetreatmentofdepression
_version_	1718403321591496704

Association between serotonin transporter polymorphisms (5-HTTLPR) and the MADRS Dysphoria, Retardation, and Vegetative Subscale scores in the treatment of depression

Ejemplares similares